Get
the Inside scoop on why Generex’s Insulin Spray is at
the front of the pack!
Generex’s
insulin spray “Oralin” is much closer to commercialization
While
“Exubera” is put on hold for 2002.
Today’s Wall Street Journal
reports that GlaxoSmithKline (NYSE: GSK), the makers of the
popular Type 2 drug Avandia, is about to sign an agreement with
Nobex Corp. to develop an oral insulin drug. While this development
is interesting the real news is what’s missing from the
article. While the article mentions Emisphere Technologies (NASDAQ:EMIS)
and Model portfolio member Generex Biotechnology (NASDAQ:GNBT)
as other companies who also in the race, NO mention is made
of Exubera (Exubera is Pfizer’s (NYSE:PFE) attempt at
inhaled insulin) or Aradigm (NASDAQ:ARDM) who’s partnered
with Model Portfolio member Novo Nordisk (NYSE:NVO).
Could it be that the street has
finally awakened to the fact that insulin that’s absorbed
through the lungs just won’t fly? Something that Diabetic
Investor has been saying for several years.
There’s no question that
should someone successfully develop a non-injectable form of
insulin that it would be a major commercial success. Diabetes
is growing at epidemic rates and insulin therapy is gaining
greater acceptance in the medical community. The fact of the
matter is, while oral medications such as Avandia do a good
job of controlling Type 2 diabetes, oral medications alone often
are not the answer. The American Diabetes Association (ADA)
estimates that there are over 1 million people with Type 1 (insulin
dependent) diabetes. However, the ADA also estimates that there
are nearly 15 million people with Type 2 (non-insulin dependent)
diabetes. Of those 15 million Type 2’s Diabetic Investor
estimates that there are nearly 3 to 4 million Type 2’s
who use insulin as part of their daily treatment regiment. Many
in the industry also believe that more Type 2’s would
use insulin if it did not have to inject. The fact is with the
majority of Type 2’s are treated by a primary care physician
who is often reluctant to prescribe insulin to their patients
because it must be injected.
In a perfect world it would be
great if insulin was available in a pill. However, there are
several significant hurdles to overcome before this ever becomes
a reality. Progress is being made but we are still years away.
Much closer to commercialization
is Generex’s insulin spray called Oralin. Unlike other
attempts at oral insulin, Oralin is not absorbed in the lungs;
it’s absorbed in the mouth. Oralin offers another advantage
over its competitors in that its delivery device is simple to
operate and looks much like an asthma inhaler. No special instructions,
the patient doesn’t have to carry a cumbersome device,
doesn’t have to wait to be breathing “properly”
– just put the device up to the mouth, push and put it
back in their pocket or purse. It’s that simple.
To date all studies indicate
that Oralin is both safe and effective, something that cannot
be said about its competitors. Currently all Phase II trials
for Oralin have been completed and the company expects to begin
Phase III trials sometime in the fall. Generex is also partnered
with Model Portfolio member Eli Lilly (NYSE:LLY).
David Kliff
Publisher
Diabetic Investor
800-783-3712
847-634-4777
847-634-4646 Fax
dkliff@diabeticinvestor.com
http://www.diabeticinvestor.com/
Printer
Friendly Version Here
